Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

UKONS 2016 | Challenges of dealing with prostate cancer patients on Radium-223

Lisa White • 10 Nov 2016
UKONS 2016
Prostate Cancer

Lisa White, Advanced Prostate Cancer CNS at Leeds Teaching Hospitals NHS Trust, UK, talks about the challenges in dealing with prostate cancer patients on Radium-223. She mentions encouraging clinicians to use Ra-223 earlier in a patient’s pathway to generate maximum benefits. The challenges of managing the patients themselves is also discuss. Patients with not just physical but emotional and social symptoms, requiring collaboration with different members of the MDT inside and outside of hospital. Recorded at Recorded at the 2016 Annual Meeting of the Oncology Nursing Society (ONS), held in Brighton, UK.

More from Lisa White

Summary of nurse-led follow-up service for prostate cancer patients on Radium-223
0:51
Summary of nurse-led follow-up service for prostate cancer patients on Radium-223
Lisa White • 10 Nov 2016
The importance of specialist nurses in the Radium-223 service for prostate cancer patients
0:42
The importance of specialist nurses in the Radium-223 service for prostate cancer patients
Lisa White • 10 Nov 2016

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals